2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.28 Efficacy and Safety of Penpulimab-Containing Regimens for Advanced Malignant Solid Tumors That Have Failed Immunotherapy: A Real World Study.

EP.11A.28 Efficacy and Safety of Penpulimab-Containing Regimens for Advanced Malignant Solid Tumors That Have Failed Immunotherapy: A Real World Study.

Back to course

Pdf Summary

The study aimed to evaluate the efficacy and safety of Penpulimab, a PD1 antibody, in patients with advanced malignant solid tumors who previously failed PD-1/PD-L1 inhibitor treatment. Conducted from September 2021 to February 2024, the study involved 26 patients with a median age of 59.9 years, comprising various cancers, including non-small cell lung cancer (NSCLC) and gastric cancer.<br /><br />The primary endpoint was the objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Findings indicated an ORR of 3.8% and a DCR of 88.5%, with a median PFS of 9.1 months. The study reported no mature data for median OS. Most patients achieved stable disease (SD), and no complete responses (CR) were observed.<br /><br />Grade 3 treatment-related adverse events (TRAEs) were seen in 17.9% of patients, with common TRAEs including anemia, decreased lymphocyte counts, hypoalbuminemia, increased thyrotropin, and hypercholesterolemia. However, the safety profile of the Penpulimab regimens appeared favorable overall.<br /><br />Two typical cases of NSCLC were highlighted. Patient No. 5, with stable disease, initially received Tislelizumab and chemotherapy, followed by treatment with Penpulimab and Anlotinib. Patient No. 1 experienced postoperative recurrence after Toripalimab, chemotherapy, and Anlotinib, then underwent additional therapy with Penpulimab and Anlotinib.<br /><br />In conclusion, the study suggests that Penpulimab-containing regimens may offer a significant therapeutic option and benefit patients with advanced solid tumors who have shown resistance to prior immunotherapy, though further investigation remains necessary.

Asset Subtitle

Juying Zhou

Meta Tag

Speaker Juying Zhou

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

Penpulimab

PD1 antibody

advanced malignant solid tumors

PD-1/PD-L1 inhibitor

objective response rate

progression-free survival

disease control rate

treatment-related adverse events

non-small cell lung cancer

immunotherapy resistance